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Updates in Cervical 
Cancer Screening
From the 2019 ASCCP Management 
Guidelines and beyond 




1. To review the incidence of cervical cancer in the United States and the 
relationship between the HPV virus and invasive cervical cancer. 
2. To review the 2019 ASCCP guidelines and how they differ from 2012 
guidelines. 




Cervical Cancer in the United States2 
HPV and Cervical Cancer 
High-risk HPV types are detected in >99% of cervical cancers.4 
HPV16 and HPV18 are implicated in >70% of cervical cancers.3 
HPV Vaccination 
June 2006: Quadrivalent (6, 11, 16, 18) HPV 
vaccine approved. Gardasil, Merck. 
October 2009: Bivalent (16, 18) HPV vaccine 
approved. Cervarix, GlaxoSmithKline. 
December 2014: 9-valent ( 6, 11, 16, 18, 31, 33, 
45, 52, 58) HPV vaccine approved. Gardasil-9, 
Merck. 
While vaccination against HPV in the United 
States is not as common as vaccination against 
other conditions, the projection is that rates of 
CIN3+ and cervical cancer will continue to 
decrease as our vaccinated cohort ages. 
Quadrivalent HPV vaccine has been associated 
with a substantially decreased risk of invasive 
cervical cancer at a population level.5 
Cervical Intraepithelial Neoplasia Progression
2012 ASCCP Consensus Guidelines6 
● First cervical cancer screening guidelines to be based on the principle, 
“Equal management for equal risk.” 
● However, 2012 guidelines still relied to some degree on complicated, 
result-based algorithms. 
● “The key difference between 2019 guidelines and previous versions is the 





Recommendations are based on risk, not results. 
7
Case #1
Patient A.A. is a 31y/o F who is seeing you as a new patient for an annual visit. 
She recently moved to Philadelphia from Georgia and does not have any of her 
previous records with her. She says that it has been at least 5 years since her last 
pap smear and does not remember if she has had any abnormal results in the 
past. 
You perform co-testing in the office and the results are: HPV+, ASCUS.
What do you tell this patient for follow-up? 
TABLE 1A: Immediate and 5-Year Risks of CIN 3+ for Abnormal 






What do you tell this patient for 
follow up? 
Table 3: CIN 3+ 1-Year and 5-Year Risks Upon Receipt of 
Colposcopy/Biopsy Results1
7
1 year follow up 
results: 
HPV+ ASCUS
What do you tell this patient for 
follow up? 
Table 4A: Immediate and 5-Year Risks of CIN 3+ Postcolposcopy at 






Repeat HPV testing or cotesting (rather than colposcopy) is recommended for patients 
with minor screening abnormalities indicating HPV infection with a low underlying risk 
of CIN3+. 
2012 ASCCP Guidelines6 
2019 ASCCP Guidelines1 
Essential Change 
#3
Guidance for expedited treatment (treatment without colposcopic biopsy) is expanded. 
2012 ASCCP Guidelines6 
2019 ASCCP Guidelines7: 
For non-pregnant patients age 25+
● Expedited treatment is preferred 
when the immediate risk of CIN 3+ ≥ 
60%
● Expedited treatment is acceptable 
for those with immediate risk of 
CIN3+ between 25% and 60% 
● Expedited treatment is preferred for 
patients with HSIL cytology an a 
concurrent +HPV16 genotype 
Case #2
A 30y/o F presents to your office for routine cervical cancer screening. She has 
no history of abnormal paps. Her results return: HPV+, NILM. How do you 
counsel her regarding follow-up? 
1
Case #2 
She follows up with you in 1 year as you recommend. This time her results 




Excisional treatment is preferred over ablative treatment for histologic HSIL. 
Adenocarcinoma in situ should be removed via excision. 
Essential Change 
#5
Observation is preferred to treatment for CIN1. 
2012 ASCCP Guidelines6 2019 ASCCP Guidelines1 
Essential Change 
#6
Addresses the use of primary HPV testing! 
“When primary HPV screening is used, performance of an additional reflex triage test 
(e.g. reflex cytology) for all positive HPV tests regardless of genotype is preferred.”
“Use of primary HPV screening will likely increase in the future, as it is more effective 
than screening with cytology alone and performs similarly to and with lower costs than 
screening with co-testing.” 7 
Who is eligible for primary HPV testing? 
2015 Interim Clinical Guidance from ASCCP, ACS, ASCP8: 
Primary hrHPV screening should not be initiated before 25 years of age.
2020 ACS Recommendations9: 
 The ACS recommends the primary HPV test as the preferred test for cervical 
cancer screening for people 25-65 years of age. 
Essential Change 
#7
Addresses surveillance with HPV testing or co-testing after treatment of histologic 
HSIL, CIN2, CIN3 or AIS. 
Continued surveillance with HPV testing 
or co-testing at 3 year intervals for at 
least 25 years is recommended after 
treatment and initial post-treatment 
management of histologic HSIL, CIN2, 
CIN3 or AIS. 
2012 ASCCP Guidelines6 2019 ASCCP Guidelines7 
There’s an app for that! 
Case #3
A 28y/o F presents to your office to review the results of her colposcopy. She had 
a prior pap smear with ASCUS, with reflex +HPV. Biopsies from her colposcopy 
show CIN1. How do you counsel her? 
ASCCP Management Guidelines App 
ASCCP Management Guidelines
1
Recommendations for practice 
● It can be challenging for those of us in primary care to keep up with 
relatively frequent changes to management guidelines, hence the 
significance of having up to date technology at our fingertips. The use of 
apps can aid PCPs in providing appropriate patient care. 
● EMR systems should contain a user-friendly interface for tracking cervical 
cancer screening results and ensuring appropriate follow up. 
Take home points - Top 3 
1. Recommendations for further management should now be based on patient 
risk, not just test results. 
2. Primary HPV screening will likely be an important component of cervical 
cancer screening in the future.  
3. Technology is your friend in keeping up to date with changing guidelines. 
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